Skip to main content
LLY
NYSE Life Sciences

FDA Approves Lilly's Selpercatinib for RET-Driven Solid Tumors

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1,154.06
Mkt Cap
$1.087T
52W Low
$623.78
52W High
$1,249.45
52W Position info
85% above low
Off High info
7.6% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

LLY sits 85% above its 52-week low of $623.78.

Summary

The FDA granted traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors, expanding the drug's label beyond its prior accelerated approvals in lung and thyroid cancers. This marks a significant regulatory win for Lilly's oncology portfolio, adding a tumor-agnostic indication that could meaningfully broaden the addressable patient population. The approval follows a series of positive pipeline developments for Lilly, including recent late-stage wins for its obesity and diabetes franchises. With a market cap over $1 trillion, the direct financial impact may be modest relative to Lilly's GLP-1 blockbusters, but it reinforces the company's diversification into high-value oncology. No specific upcoming catalysts were mentioned.

At the time of this announcement, LLY was trading at $1,154.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 18, 2026, 3:04 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,381.18
Real-time Price: $1,357.50 info
Change: -$23.68 (-2%) info
Market Cap: $1.271T info
LLY
Nov 17, 2026, 11:18 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,416.23
Real-time Price: $1,357.50 info
Change: -$58.72 (-4%) info
Market Cap: $1.271T info
LLY
Nov 16, 2026, 6:52 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,455.36
Real-time Price: $1,357.50 info
Change: -$97.86 (-7%) info
Market Cap: $1.271T info
LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,357.50 info
Change: -$95.19 (-7%) info
Market Cap: $1.271T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,357.50 info
Change: -$90.35 (-6%) info
Market Cap: $1.271T info